According to the website of the State Food and Drug Administration, on July 25, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the “Drug Administration Law” and in accordance with the special approval procedures for drugs, and approved Henan Zhenzhen Biotechnology Co., Ltd. with conditions. The registration application for zivudine tablets for the treatment of new coronavirus pneumonia has been increased.
This product is an oral small molecule novel coronavirus pneumonia treatment drug independently developed by my country. On July 20, 2021, the State Food and Drug Administration has conditionally approved this product in combination with other reverse transcriptase inhibitors for the treatment of adult HIV-1 infected patients with high viral load. This is a conditional approval of an additional indication for the treatment of adult patients with common novel coronavirus pneumonia (COVID-19). Patients should strictly follow the instructions for medication under the guidance of a physician.
The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner.
[Source: State Drug Administration]
Disclaimer: The copyright of this article belongs to the original author All, if the source is wrong or violates your legal rights, you can contact us by email, and we will deal with it in time. Email address: [email protected]